GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Gross Margin %

Twist Bioscience (Twist Bioscience) Gross Margin %

: 40.51% (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Twist Bioscience's Gross Profit for the three months ended in Dec. 2023 was $29.0 Mil. Twist Bioscience's Revenue for the three months ended in Dec. 2023 was $71.5 Mil. Therefore, Twist Bioscience's Gross Margin % for the quarter that ended in Dec. 2023 was 40.51%.


The historical rank and industry rank for Twist Bioscience's Gross Margin % or its related term are showing as below:

TWST' s Gross Margin % Range Over the Past 10 Years
Min: -315.2   Med: 22.33   Max: 41.38
Current: 35.79


During the past 8 years, the highest Gross Margin % of Twist Bioscience was 41.38%. The lowest was -315.20%. And the median was 22.33%.

TWST's Gross Margin % is ranked worse than
67.59% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.155 vs TWST: 35.79

Twist Bioscience had a gross margin of 40.51% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Twist Bioscience was 0.00% per year.


Twist Bioscience Gross Margin % Historical Data

The historical data trend for Twist Bioscience's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only 12.80 31.85 39.08 41.38 36.61

Twist Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.72 30.76 34.35 36.63 40.51

Competitive Comparison

For the Diagnostics & Research subindustry, Twist Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience Gross Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Gross Margin % falls into.



Twist Bioscience Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Twist Bioscience's Gross Margin for the fiscal year that ended in Sep. 2023 is calculated as

Gross Margin % (A: Sep. 2023 )=Gross Profit (A: Sep. 2023 ) / Revenue (A: Sep. 2023 )
=89.7 / 245.109
=(Revenue - Cost of Goods Sold) / Revenue
=(245.109 - 155.38) / 245.109
=36.61 %

Twist Bioscience's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=29 / 71.498
=(Revenue - Cost of Goods Sold) / Revenue
=(71.498 - 42.536) / 71.498
=40.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Twist Bioscience  (NAS:TWST) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Twist Bioscience had a gross margin of 40.51% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Twist Bioscience Gross Margin % Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Twist Bioscience (Twist Bioscience) Business Description

Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Executives
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Dennis Cho officer: See Remarks C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Melissa A. Starovasnik director C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen director 5555 NE MOORE CT., HILLSBORO OR 97124
William Banyai director, officer: Chief Operating Officer C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green officer: VP of Human Resources C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
James M Thorburn officer: Chief Financial Officer C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Robert Chess director
Patrick John Finn officer: VP of Sales and Marketing C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Emily M. Leproust director, officer: President & CEO C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Patrick Weiss officer: VP of Operations C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton officer: Chief Accounting Officer 1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels officer: Chief Compliance Officer & GC C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158